Skip to content

Search Results

No Matching Results

    Recently Viewed

      Listening...

      HomeOur CompanyOur societal impact Global Public HealthWhy now is the time to tackle DR-TB
      Dr. Paul Stoffels speaking on camera during segment on efforts to combat drug-resistant tuberculosis
      Global Public Health

      Why now is the time to tackle DR-TB

      Share Article
      share to

      Drug-resistant TB (DR-TB) is on the rise with 558,000 new cases a year. It is the only airborne drug-resistant epidemic and responsible for nearly 1/3 of all deaths from antimicrobial resistance (AMR) globally.

      A new report by The Economist Intelligence Unit (EIU), and made possible with support from Johnson & Johnson, emphasizes the urgent need for global action to address the growing threat of DR-TB.

      Learn more.

      You are now leaving jnj.com. The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.